ChromoCure, Inc. Announces Major Therapeutics Research "Project Boveri: Find the Cure"
03 February 2010 - 12:30AM
Marketwired
ChromoCure, Inc. (PINKSHEETS: KKUR) announced today the launch of a
major new research initiative targeting Cancer Therapy and Cure.
The Company has realigned its business strategy due to
corroboration by recent Medical Research publications that both
validated ChromoCure's chromosomal/aneuploidy theory of cancer and
immediately established the company's proprietary ChromoSomal
Scanner technology in the forefront of both cancer detection and
research. The company will announce new partnerships, products,
licensing, and laboratory activities based on this
research-oriented alignment.
Research has conclusively, and irrefutably demonstrated
aneuploidy as a more accurate predictor of cancer than
cytological/histological analysis or genetic marker-based
diagnostics that are the only other methods in existence today.
ChromoCure's proprietary technology and understanding of cancer
also suggest non-toxic and non-invasive approaches to cancer
therapy and cure research.
The company's technology and research combined with unique
insights provided by the chromosomal theory of cancer paves the way
for non-invasive and non-toxic solutions to cancer therapeutics and
disease eradication. ChromoCure's ChromoSomal Scanner Technologies,
encompassing proprietary designs, processes, and algorithms,
provides significant advantage in delivering important and
significant results in both therapy and cure.
Support by these recent third party medical findings, the
Company is calling for a stepped up collaborative approach through
its "Project Boveri: Find the Cure" initiative; and is inviting
industry, institutions, medical research centers and government to
partner in this initiative. The company has already established a
special section of its web site dedicated to this project and
research outreach. The Company's recently announced diagnostic
partnership program with pathologists and diagnostic labs will be
incorporated into Project Boveri in order to broaden awareness of
the company's technology.
The company will provide cancer detection and progression
measurement services using its own equipment to research partners
participating in the Project Boveri initiative. "Project Boveri" is
named after Theodor Boveri who first described the
chromosomal/aneuploidy theory of cancer diagnosis nearly a century
ago.
The company will soon announce the details on various
collaborative research centers participating in "Project Boveri:
Find the Cure".
About ChromoCure
ChromoCure develops and provides proprietary cancer detection
systems and technologies. The Company's proprietary ChromoCure
CS200 Chromosomal Scanner system has been proven accurate and
efficient in the measurement of the unique genomic characteristic
found in 100% of all cancers and never found in normal cells. The
Company's detection technology has been proven to have an effective
accuracy of 100% for all cancers at all stages. The Company
believes its technology will become the worldwide gold standard for
cancer detection, progression measurement, and research for both
therapy and cure.
Safe-Harbor Statement
This release contains statements or projections regarding future
performance that is forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those projected as a result of certain
risks and uncertainties. The company's filings contain various RISK
FACTORS (and are incorporated herein by reference) and should be
read before any investment decision.
ChromoCure, Inc. www.ChromoCure.com info@chromocure.com Tel
1.775.636.654
Chromocure (CE) (USOTC:KKUR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Chromocure (CE) (USOTC:KKUR)
Historical Stock Chart
From Sep 2023 to Sep 2024